<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JPP</journal-id>
<journal-id journal-id-type="hwp">spjpp</journal-id>
<journal-title>Journal of Pharmacy Practice</journal-title>
<issn pub-type="ppub">0897-1900</issn>
<issn pub-type="epub">1531-1937</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0897190012448309</article-id>
<article-id pub-id-type="publisher-id">10.1177_0897190012448309</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacogenomics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical Application of Pharmacogenomics <inline-graphic xlink:href="10.1177_0897190012448309-fig1.tif"/></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ma</surname>
<given-names>Joseph D.</given-names>
</name>
<degrees>PharmD</degrees>
<xref ref-type="aff" rid="aff1-0897190012448309">1</xref>
<xref ref-type="corresp" rid="corresp1-0897190012448309"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Kelly C.</given-names>
</name>
<degrees>PharmD, BCPP</degrees>
<xref ref-type="aff" rid="aff1-0897190012448309">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kuo</surname>
<given-names>Grace M.</given-names>
</name>
<degrees>PharmD, MPH, PhD</degrees>
<xref ref-type="aff" rid="aff1-0897190012448309">1</xref>
</contrib>
<aff id="aff1-0897190012448309"><label>1</label>Skaggs School of Pharmacy &amp; Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA</aff>
</contrib-group>
<contrib-group content-type="issue">
<contrib contrib-type="guest-editor">
<name>
<surname>Saltiel</surname>
<given-names>Manny</given-names>
</name>
<degrees>PharmD, FASHP, FCCP</degrees>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0897190012448309">Joseph D. Ma, Skaggs School of Pharmacy &amp; Pharmaceutical Sciences, University of California, La Jolla, CA 92093, USA Email: <email>joema@ucsd.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>25</volume>
<issue>4</issue>
<fpage>417</fpage>
<lpage>427</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The purpose of this review is to discuss the clinical application of pharmacogenomics for select drug therapies (eg, proton pump inhibitors [PPIs], codeine, and carbamazepine) and to highlight limitations and challenges that preclude implementation of pharmacogenomics into clinical practice. Genetic polymorphisms of cytochrome P450 (CYP) enzymes and the presence of the human leukocyte antigen (<italic>HLA</italic>)<italic>-B*1502</italic> allele influence drug disposition and/or response. A portion of PPI pharmacokinetic and pharmacodynamic variability can be explained by <italic>CYP2C19 </italic>genotype. However, conflicting evidence exists related to <italic>Helicobacter pylori </italic>cure rates based on <italic>CYP2C19 </italic>genotype. For codeine, adverse drug reactions in neonates through breast-feeding from <italic>CYP2D6 </italic>ultra-rapid metabolizers have been reported. However, there is lack of conclusive evidence regarding the overall influence of <italic>CYP2D6 </italic>polymorphisms on codeine efficacy and toxicity. Although <italic>CYP2C19 </italic>and <italic>CYP2D6 </italic>genotyping tests are available, clinical utility remains low. The presence of the <italic>HLA-B*1502</italic> allele is associated with carbamazepine-induced Stevens-Johnson syndrome (SJS) and/or toxic epidermal necrolysis (TEN). Pharmacogenomic testing is required prior to initiating carbamazepine in high-risk patients. Lack of sufficient resources, provider knowledge, and ethical, legal, and social issues are several limitations and challenges to implementing pharmacogenomic testing in clinical practice.</p>
</abstract>
<kwd-group>
<kwd>pharmacogenomics</kwd>
<kwd>pharmacogenetics</kwd>
<kwd>proton pump inhibitors</kwd>
<kwd>codeine</kwd>
<kwd>carbamazepine</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0897190012448309">
<title>Learning Objectives</title>
<p>At the conclusion of this article, the participant will be able to:</p>
<list list-type="order">
<list-item>
<p>Identify the functional effects of select genetic polymorphisms and the impact on drug dosing, efficacy, and/or toxicity.</p>
</list-item>
<list-item>
<p>Describe pharmacogenomic tests for select medications based on current evidence for testing recommendations and clinical use.</p>
</list-item>
<list-item>
<p>Discuss currently available evidence-based recommendations for pharmacogenomic testing for select medications.</p>
</list-item>
<list-item>
<p>State at least one study design limitation that is observed in pharmacogenomic studies.</p>
</list-item>
<list-item>
<p>State at least one challenge that affects implementation of pharmacogenomic testing into clinical practice.</p>
</list-item>
</list>
</sec>
<sec id="section2-0897190012448309">
<title>Introduction</title>
<p>Pharmacogenomics is a rapidly developing field that has important potential clinical application on individualizing therapy to maximize efficacy and/or minimize toxicity. Numerous, but similar definitions of pharmacogenetics/pharmacogenomics have been proposed by professional organizations, regulatory agencies, and researchers. Pharmacogenetics is defined as “the study of genetic causes of individual variations in drug response.”<sup>
<xref ref-type="bibr" rid="bibr1-0897190012448309">1</xref>
</sup> Pharmacogenomics is defined as “the genome-wide analysis of genetic determinants of drug efficacy and toxicity.”<sup>
<xref ref-type="bibr" rid="bibr2-0897190012448309">2</xref>
</sup> While pharmacogenetics focuses on a single or a few genes, pharmacogenomics examines genes in all chromosomes. Although pharmacogenetics and pharmacogenomics are used interchangeably, for purposes of this review, the preferred term will be pharmacogenomics.</p>
<p>This review discusses the pharmacogenomics of specific drug therapies (eg, proton pump inhibitors [PPIs], codeine, and carbamazepine) and highlights the limitations and challenges with clinical applications of pharmacogenomics testing. Each example will discuss (1) background, (2) gene/allele of interest and functional effect, (3) population prevalence, (4) clinical relevance of the polymorphism related to dosing, efficacy, and/or toxicity, and (5) pharmacogenomic testing and recommendations. The therapeutic areas were selected based upon the level of evidence for testing recommendations that either support or refute the role of pharmacogenomic testing and clinical utility. Clinical utility was based upon the frequency of pharmacogenomic testing in the clinical setting. For example, with carbamazepine, the level of evidence of pharmacogenomic testing is high as well as its clinical utility. Regarding codeine, the level of evidence for pharmacogenomic testing is moderate, while the clinical utility is low at this time. Reviews of pharmacogenomic principles, concepts, and nomenclature are published elsewhere<sup>
<xref ref-type="bibr" rid="bibr3-0897190012448309">3</xref>,<xref ref-type="bibr" rid="bibr4-0897190012448309">4</xref>
</sup> and will not be discussed. </p>
</sec>
<sec id="section3-0897190012448309">
<title>Understanding the Clinical Significance of Polymorphisms</title>
<p>A polymorphism for a specific protein may vary in terms of the functional effect, population prevalence, and clinical relevance. Consequently, a systematic approach to understanding polymorphisms is suggested (<xref ref-type="table" rid="table1-0897190012448309">Table 1</xref>). Since proteins are generally affected by the polymorphism, it is important to first identify the polymorphism. Enzymes, drug transporters, and/or receptors are examples of proteins that are genetically polymorphic, of which the functional effect can result in increased, decreased, or no change in protein activity. The next step is to consider whether population variation exists for a polymorphism. Examples exist where a polymorphism is present in a higher frequency in a specific ethnic group.<sup>
<xref ref-type="bibr" rid="bibr5-0897190012448309">5</xref>
</sup> In determining clinical relevance, relationships between the polymorphism and drug and disease for an individual should be examined. Drug dosing, efficacy, toxicity, pharmacokinetics, and/or pharmacodynamics may be affected by the polymorphism. A polymorphism may also influence disease prognosis, susceptibility, or be used as a screening test for certain diseases.<sup>
<xref ref-type="bibr" rid="bibr6-0897190012448309">6</xref>
</sup>
</p>
<table-wrap id="table1-0897190012448309" position="float">
<label>Table 1.</label>
<caption>
<p>Systematic Approach to Understanding Polymorphisms<sup><xref ref-type="table-fn" rid="table-fn1-0897190012448309">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table1-0897190012448309" xlink:href="10.1177_0897190012448309-table1.tif"/>
<table>
<tbody>
<tr>
<td>1. Identify the polymorphism and affected protein.</td>
</tr>
<tr>
<td>2. Identify whether population variation exists for a specific polymorphism.</td>
</tr>
<tr>
<td>3. Determine the relationship between the polymorphism and a drug for an individual, whether there is a change or no change in drug dosing, efficacy, toxicity, pharmacokinetics, and/or pharmacodynamics.</td>
</tr>
<tr>
<td>4. Determine the relationship between the polymorphism and a disease for an individual.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0897190012448309">
<p>
<sup>a</sup> Reprinted from Joseph Ma, “Module I: Principles and Concepts, PharmGenEd™ Program.” July 16, 2009, by permission of PharmGenEd™. Copyright <italic>© </italic>2009 Regents of the University of California. All rights reserved.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section4-0897190012448309">
<title>Examples of Clinical Application of Pharmacogenomics</title>
<sec id="section5-0897190012448309">
<title>Proton Pump Inhibitors</title>
<sec id="section6-0897190012448309">
<title>Background</title>
<p>PPIs (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and rabeprazole) are indicated for treatment of various gastric acid-related disorders (eg, duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and Zollinger-Ellison syndrome). They are used in combination with 1 or 2 antibiotics for <italic>Helicobactor pylori</italic> (<italic>H pylori</italic>) eradication.<sup>
<xref ref-type="bibr" rid="bibr7-0897190012448309">7</xref>,<xref ref-type="bibr" rid="bibr8-0897190012448309">8</xref>
</sup> PPIs are irreversible inhibitors of the H<sup>+</sup>/K<sup>+</sup> ATPase pump, thus impacting acid secretion in the gastric tract. Detailed reviews of PPI pharmacokinetics are published elsewhere.<sup>
<xref ref-type="bibr" rid="bibr8-0897190012448309">8</xref>,<xref ref-type="bibr" rid="bibr9-0897190012448309">9</xref>
</sup> Omeprazole, esomeprazole, lansoprazole, and pantoprazole are primarily metabolized by <italic>CYP2C19</italic> and to some extent by <italic>CYP3A</italic>. However, the extent of <italic>CYP2C19</italic> and <italic>CYP3A</italic> metabolism between PPIs is variable.<sup>
<xref ref-type="bibr" rid="bibr10-0897190012448309">10</xref>
</sup> Rabeprazole is predominantly metabolized via nonenzymatic reduction to a thioether.<sup>
<xref ref-type="bibr" rid="bibr8-0897190012448309">8</xref>,<xref ref-type="bibr" rid="bibr11-0897190012448309">11</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section7-0897190012448309">
<title>Gene/Allele of Interest and Functional Effect</title>
<p>The <italic>CYP2C19</italic> gene is located on chromosome 10 (10q24.1-q24.3) and contains 9 exons.<sup>
<xref ref-type="bibr" rid="bibr12-0897190012448309">12</xref>,<xref ref-type="bibr" rid="bibr13-0897190012448309">13</xref>
</sup> <italic>CYP2C19*1 </italic>codes for normal (wild-type) enzyme activity. At least 27 variant alleles for <italic>CYP2C19</italic> have been identified,<sup>
<xref ref-type="bibr" rid="bibr14-0897190012448309">14</xref>
</sup> with the most extensively described variant alleles being <italic>CYP2C19*2 </italic>and <italic>CYP2C19*3.</italic> Regarding <italic>CYP2C19*2</italic>, a splicing defect in exon 5 occurs, resulting in early termination of protein synthesis.<sup>
<xref ref-type="bibr" rid="bibr15-0897190012448309">15</xref>
</sup> <italic>CYP2C19*3 </italic>is a premature stop codon single-nucleotide polymorphism, which results in a truncated protein. The functional effect of these polymorphisms is a complete loss of (or null) enzyme activity. Other <italic>CYP2C19 </italic>alleles result in a loss of (<italic>CYP2C19*4-*8</italic>) or reduced (<italic>CYP2C19*9, *10, </italic>and <italic>*12</italic>) enzyme activity.<sup>
<xref ref-type="bibr" rid="bibr14-0897190012448309">14</xref>,<xref ref-type="bibr" rid="bibr16-0897190012448309">16</xref>
</sup> In contrast, increased enzyme activity is associated with <italic>CYP2C19*17</italic>.<sup>
<xref ref-type="bibr" rid="bibr17-0897190012448309">17</xref>
</sup>
</p>
</sec>
<sec id="section8-0897190012448309">
<title>Population Prevalence</title>
<p>In caucasians, Asians, and African Americans, <italic>CYP2C19*2 </italic>frequencies are approximately 15%, 30%, and 17%, respectively, while the <italic>CYP2C19*3 </italic>frequencies are approximately 0.04%, 5%, and 0.4%, respectively.<sup>
<xref ref-type="bibr" rid="bibr9-0897190012448309">9</xref>,<xref ref-type="bibr" rid="bibr18-0897190012448309">18</xref>
<xref ref-type="bibr" rid="bibr19-0897190012448309"/>–<xref ref-type="bibr" rid="bibr20-0897190012448309">20</xref>
</sup> Allele frequencies for <italic>CYP2C19*17 </italic>are approximately 18% in caucasian and Ethiopian populations and 4% in Asian populations.<sup>
<xref ref-type="bibr" rid="bibr21-0897190012448309">21</xref>
</sup>
</p>
<p>A gene–dose effect is commonly observed for medications metabolized by <italic>CYP2C19</italic>, thereby allowing stratification of subjects by <italic>CYP2C19 </italic>genotype. <italic>CYP2C19 </italic>homozygous extensive metabolizers (EMs) are individuals who possess 2 wild-type alleles, <italic>CYP2C19 </italic>heterozygous EMs are individuals who possess 1 wild-type and 1 decreased/null variant allele, and <italic>CYP2C19 </italic>poor metabolizers (PMs) are individuals who possess 2 decreased/null activity alleles.<sup>
<xref ref-type="bibr" rid="bibr22-0897190012448309">22</xref>
</sup> The population prevalence of <italic>CYP2C19 </italic>PMs ranges from 1% to 4%, 15% to 23%, and 2% to 7% in caucasians, Asians, and African Americans, respectively.<sup>
<xref ref-type="bibr" rid="bibr18-0897190012448309">18</xref>
</sup>
</p>
</sec>
<sec id="section9-0897190012448309">
<title>Clinical Relevance</title>
<p>Although <italic>H pylori </italic>dual/triple therapies for eradication vary in terms of PPI use and in PPI dosing, there are currently no published studies that have examined PPI dosing strategies based on <italic>CYP2C19 </italic>genotype. This may be due to the large therapeutic window of PPIs, low incidence of clinically significant adverse effects, and multitude of dual/triple therapy regimens that are available. There is suggestion that higher PPI doses be considered in homozygous EMs, yet it remains to be implemented in clinical practice.<sup>
<xref ref-type="bibr" rid="bibr23-0897190012448309">23</xref>
</sup>
</p>
<p>The majority of clinically relevant data have focused on the effect of <italic>CYP2C19 </italic>genotypes on <italic>H pylori </italic>eradication, with little attention to adverse effect risk. PPIs are unique in that pharmacokinetic (PK) variability affects pharmacodynamic (PD) variability. Omeprazole area under the concentration–time curve (AUC) is 7- to 14-fold higher in PMs compared to homozygous EMs.<sup>
<xref ref-type="bibr" rid="bibr24-0897190012448309">24</xref>
<xref ref-type="bibr" rid="bibr25-0897190012448309"/>–<xref ref-type="bibr" rid="bibr26-0897190012448309">26</xref>
</sup> Omeprazole AUC correlates with intragastric pH (<italic>r</italic> = .87, <italic>P</italic> &lt; .0001), of which <italic>CYP2C19</italic> PMs have higher intragastric pH concentrations compared to <italic>CYP2C19 </italic>EMs.<sup>
<xref ref-type="bibr" rid="bibr26-0897190012448309">26</xref>,<xref ref-type="bibr" rid="bibr27-0897190012448309">27</xref>
</sup> A higher intragastric pH has been shown to increase antibiotic concentrations and improve antibiotic bioavailability and stability.<sup>
<xref ref-type="bibr" rid="bibr28-0897190012448309">28</xref>
<xref ref-type="bibr" rid="bibr29-0897190012448309"/>
<xref ref-type="bibr" rid="bibr30-0897190012448309"/>–<xref ref-type="bibr" rid="bibr31-0897190012448309">31</xref>
</sup>
</p>
<p>The PK and PD variabilities for PPIs, explained to some extent by <italic>CYP2C19 </italic>genetic polymorphisms, have resulted in different <italic>H pylori </italic>cure rates. In one study, Japanese patients (n = 62) with confirmed <italic>H pylori </italic>infection were administered dual therapy with omeprazole and amoxicillin for several weeks. <italic>H pylori </italic>cure rates were 28.6%, 60%, and 100% in homozygous EMs, heterozygous EMs, and PMs, respectively (<xref ref-type="table" rid="table2-0897190012448309">Table 2</xref>).<sup>
<xref ref-type="bibr" rid="bibr23-0897190012448309">23</xref>
</sup> These results are consistent with a majority of studies with omeprazole.<sup>
<xref ref-type="bibr" rid="bibr32-0897190012448309">32</xref>
<xref ref-type="bibr" rid="bibr33-0897190012448309"/>
<xref ref-type="bibr" rid="bibr34-0897190012448309"/>
<xref ref-type="bibr" rid="bibr35-0897190012448309"/>–<xref ref-type="bibr" rid="bibr36-0897190012448309">36</xref>
</sup> In addition, several meta-analyses have concluded that omeprazole efficacy is dependent on <italic>CYP2C19 </italic>genotype.<sup>
<xref ref-type="bibr" rid="bibr37-0897190012448309">37</xref>,<xref ref-type="bibr" rid="bibr38-0897190012448309">38</xref>
</sup>
</p>
<table-wrap id="table2-0897190012448309" position="float">
<label>Table 2.</label>
<caption>
<p>Select Examples of <italic>H pylori </italic>Cure Rates Based on <italic>CYP2C19 </italic>Genotype</p>
</caption>
<graphic alternate-form-of="table2-0897190012448309" xlink:href="10.1177_0897190012448309-table2.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Drug Regimen</th>
<th colspan="3">
<italic>H pylori </italic>Cure Rates (n)</th>
<th/>
<th/>
<th/>
<th rowspan="2">Reference</th>
</tr>
<tr>
<th>Homozygous EMs<sup><xref ref-type="table-fn" rid="table-fn3-0897190012448309">a</xref></sup>
</th>
<th>Heterozygous EMs<sup><xref ref-type="table-fn" rid="table-fn4-0897190012448309">b</xref></sup>
</th>
<th>PMs<sup><xref ref-type="table-fn" rid="table-fn5-0897190012448309">c</xref></sup>
</th>
<th>Homozygous EMs vs PMs</th>
<th>Homozygous EMs vs heterozygous EMs</th>
<th>Heterozygous EMs vs PMs</th>
</tr>
</thead>
<tbody>
<tr>
<td>OMP 20 mg QD 6 or 8 weeks, AMOX 500 mg QID 2 weeks</td>
<td>28.6% (28)</td>
<td>60% (25)</td>
<td>100% (9)</td>
<td>
<italic>P</italic> &lt; .05</td>
<td>
<italic>P</italic> &lt; .001</td>
<td>
<italic>P</italic> &lt; .05</td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr23-0897190012448309">23</xref>
</sup>
</td>
</tr>
<tr>
<td>OMP 20 mg BID, AMOX 500 mg BID 2 weeks</td>
<td>73.9% (23)</td>
<td>68.8% (80)</td>
<td>83.3% (18)</td>
<td align="center">NS</td>
<td align="center">NS</td>
<td align="center">NS</td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr40-0897190012448309">40</xref>
</sup>
</td>
</tr>
<tr>
<td>OMP 20 mg BID, AMOX 500 mg TID, CLAR 200 mg TID 1 week</td>
<td>76.2% (21)</td>
<td>88.9% (27)</td>
<td>90% (10)</td>
<td align="center">NS</td>
<td align="center">NS</td>
<td align="center">NS</td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr41-0897190012448309">41</xref>
</sup>
</td>
</tr>
<tr>
<td>LANS 30 mg BID or OMP 20 mg BID, AMOX 500 mg TID, CLAR 200 mg TID 1 week</td>
<td>72.7% (88)</td>
<td>92.1% (127)</td>
<td>97.8% (46)</td>
<td>
<italic>P</italic> &lt; .001</td>
<td>
<italic>P</italic> &lt; .001</td>
<td align="center">NS</td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr42-0897190012448309">42</xref>
</sup>
</td>
</tr>
<tr>
<td>LANS 30 mg BID, AMOX 500 mg TID, CLAR 200 mg TID 1 week</td>
<td>90% (20)</td>
<td>89.7% (29)</td>
<td>88.9% (9)</td>
<td align="center">NS</td>
<td align="center">NS</td>
<td align="center">NS</td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr41-0897190012448309">41</xref>
</sup>
</td>
</tr>
<tr>
<td>LANS 30 mg BID, AMOX 1000 mg BID, CLAR 200 mg BID, METR 400 mg BID 5 days</td>
<td>80.2% (86)</td>
<td>97.8% (42)</td>
<td>100% (3)</td>
<td>
<italic>P</italic> &lt; .05<sup><xref ref-type="table-fn" rid="table-fn6-0897190012448309">d</xref></sup>
</td>
<td>
</td>
<td>
</td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr46-0897190012448309">46</xref>
</sup>
</td>
</tr>
<tr>
<td>RABE 10 mg BID, AMOX 500 mg TID 2 weeks</td>
<td>60.6% (33)</td>
<td>91.7% (48)</td>
<td>93.8% (16)</td>
<td>
<italic>P</italic> = .001</td>
<td>
<italic>P</italic> = .01</td>
<td align="center">NS</td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr47-0897190012448309">47</xref>
</sup>
</td>
</tr>
<tr>
<td>RABE 10 mg BID, AMOX 500 mg TID 2 weeks</td>
<td>71.4% (83)</td>
<td>77.1% (35)</td>
<td>73.3% (15)</td>
<td align="center">NS</td>
<td align="center">NS</td>
<td align="center">NS</td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr40-0897190012448309">40</xref>
</sup>
</td>
</tr>
<tr>
<td>RABE 10 mg BID, AMOX 500 mg TID, CLAR 200 mg TID 1 week</td>
<td>62.5% (24)</td>
<td>87.1% (31)</td>
<td>87.5% (8)</td>
<td align="center">NS</td>
<td>
<italic>P</italic> &lt; .05</td>
<td align="center">NS</td>
<td>
<sup>
<xref ref-type="bibr" rid="bibr41-0897190012448309">41</xref>
</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0897190012448309">
<p>Abbreviations: AMOX, amoxicillin, BID, twice daily, CLAR, clarithromycin, <italic>CYP2C19,</italic>cytochrome P450 2C19, EMs, extensive metabolizers, <italic>H pylori</italic>, <italic>Helicobacter pylori,</italic> LANS, lansoprazole, METR, metronidazole, OMP, omeprazole, PMs, poor metabolizers, NS, not significant, QD, once daily, QID, 4 times daily, RABE, rabeprazole, TID, 3 times daily.</p>
</fn>
<fn id="table-fn3-0897190012448309">
<p>
<sup>a</sup> Homozygous EMs = <italic>CYP2C19*1/*1</italic>.</p>
</fn>
<fn id="table-fn4-0897190012448309">
<p>
<sup>b</sup> Heterozygous EMs = <italic>CYP2C19*1/*2, CYP2C19*1/*3</italic>.</p>
</fn>
<fn id="table-fn5-0897190012448309">
<p>
<sup>c</sup> PMs = <italic>CYP2C19*2/*2, CYP2C19*2/*3, CYP2C19*3*3.</italic>
</p>
</fn>
<fn id="table-fn6-0897190012448309">
<p>
<sup>d</sup> <italic>P</italic> value was between homozygous EMs versus heterozygous EMs and PMs.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>There are conflicting data regarding no difference in <italic>H pylori </italic>cure rates based on <italic>CYP2C19 </italic>genotype for omeprazole (<xref ref-type="table" rid="table2-0897190012448309">Table 2</xref>).<sup>
<xref ref-type="bibr" rid="bibr39-0897190012448309">39</xref>
<xref ref-type="bibr" rid="bibr40-0897190012448309"/>–<xref ref-type="bibr" rid="bibr41-0897190012448309">41</xref>
</sup> In one study, triple therapy with omeprazole, amoxicillin, and clarithromycin for 1 week was administered to patients with <italic>H pylori </italic>confirmed peptic ulcer disease (n = 183). <italic>H pylori </italic>cure rates were 76.2%, 88.9%, and 90% in homozygous EMs, heterozygous EMs, and PMs, respectively, with no difference based on <italic>CYP2C19 </italic>genotype (<xref ref-type="table" rid="table2-0897190012448309">Table 2</xref>).<sup>
<xref ref-type="bibr" rid="bibr41-0897190012448309">41</xref>
</sup> Conflicting data also exist for lansoprazole,<sup>
<xref ref-type="bibr" rid="bibr35-0897190012448309">35</xref>,<xref ref-type="bibr" rid="bibr41-0897190012448309">41</xref>
<xref ref-type="bibr" rid="bibr42-0897190012448309"/>
<xref ref-type="bibr" rid="bibr43-0897190012448309"/>
<xref ref-type="bibr" rid="bibr44-0897190012448309"/>
<xref ref-type="bibr" rid="bibr45-0897190012448309"/>–<xref ref-type="bibr" rid="bibr46-0897190012448309">46</xref>
</sup> rabeprazole,<sup>
<xref ref-type="bibr" rid="bibr39-0897190012448309">39</xref>
<xref ref-type="bibr" rid="bibr40-0897190012448309"/>–<xref ref-type="bibr" rid="bibr41-0897190012448309">41</xref>,<xref ref-type="bibr" rid="bibr47-0897190012448309">47</xref>
<xref ref-type="bibr" rid="bibr48-0897190012448309"/>
<xref ref-type="bibr" rid="bibr49-0897190012448309"/>–<xref ref-type="bibr" rid="bibr50-0897190012448309">50</xref>
</sup> and pantoprazole (<xref ref-type="table" rid="table2-0897190012448309">Table 2</xref>).<sup>
<xref ref-type="bibr" rid="bibr51-0897190012448309">51</xref>,<xref ref-type="bibr" rid="bibr52-0897190012448309">52</xref>
</sup> Comparisons between studies are complicated due to the differences in the dual or triple drug regimens used and variability in PPI and/or antibiotic dosing.</p>
</sec>
<sec id="section10-0897190012448309">
<title>Testing Availability and Recommendations</title>
<p>A Food and Drug Administration (FDA)-approved test is commercially available (AmpliChip<sup>®</sup> CYP450, Roche Diagnostics, Indianapolis, IN) for <italic>CYP2C19</italic> genotyping. A whole blood sample is collected, DNA is extracted and then tested by a polymerase chain reaction–based microarray that analyzes the presence or absence of <italic>CYP2C19*2 </italic>and <italic>*3 </italic>alleles. Currently, there are no <italic>CYP2C19 </italic>testing recommendations for PPIs. The clinical pharmacology and drug–drug interaction sections in the prescribing information for esomeprazole, pantoprazole, and rabeprazole have been revised but with no recommendations for testing.<sup>
<xref ref-type="bibr" rid="bibr53-0897190012448309">53</xref>
</sup> Recent publications of PPI use in patients who are on antiplatelet therapy<sup>
<xref ref-type="bibr" rid="bibr54-0897190012448309">54</xref>
</sup> have influenced professional organizations to publish expert consensus statements. For managing therapy with thienopyridines and PPIs, the American College of Cardiology Foundation/the American College of Gastroenterology/the American Heart Association state that <italic>CYP2C19 </italic>testing has “not yet been established.”<sup>
<xref ref-type="bibr" rid="bibr55-0897190012448309">55</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section11-0897190012448309">
<title>Codiene</title>
<sec id="section12-0897190012448309">
<title>Background</title>
<p>Codeine is a weak opiate agonist in the central nervous system and is indicated for the relief of mild to moderately severe pain.<sup>
<xref ref-type="bibr" rid="bibr56-0897190012448309">56</xref>
</sup> Codeine is a prodrug that converts to an active metabolite, morphine, via <italic>CYP2D6</italic> by <italic>O</italic>-demethylation to exert its analgesic activity.<sup>
<xref ref-type="bibr" rid="bibr57-0897190012448309">57</xref>
<xref ref-type="bibr" rid="bibr58-0897190012448309"/>–<xref ref-type="bibr" rid="bibr59-0897190012448309">59</xref>
</sup>
</p>
</sec>
<sec id="section13-0897190012448309">
<title>Gene/Allele of Interest and Functional Effect</title>
<p>The <italic>CYP2D6</italic> enzyme catalyzes hydroxylation or demethylation of multiple drugs such as neuroleptics, antidepressants, some beta-blockers, and codeine.<sup>
<xref ref-type="bibr" rid="bibr60-0897190012448309">60</xref>
</sup> The <italic>CYP2D6 </italic>gene is located on chromosome 22, with at least 80 known variants of <italic>CYP2D6.</italic>
<sup>
<xref ref-type="bibr" rid="bibr14-0897190012448309">14</xref>
</sup> The interindividual variability of <italic>CYP2D6</italic> enzyme activity can be explained by factors such as the genetic variation of <italic>CYP2D6</italic>.<sup>
<xref ref-type="bibr" rid="bibr61-0897190012448309">61</xref>
<xref ref-type="bibr" rid="bibr62-0897190012448309"/>–<xref ref-type="bibr" rid="bibr63-0897190012448309">63</xref>
</sup> Genetic polymorphisms of <italic>CYP2D6</italic> include phenotyping subgroups of PM, intermediate metabolizer (IM), EM, and ultra-rapid metabolizer (UM).<sup>
<xref ref-type="bibr" rid="bibr58-0897190012448309">58</xref>,<xref ref-type="bibr" rid="bibr59-0897190012448309">59</xref>
</sup> The EMs are considered to have normal enzyme activity.<sup>
<xref ref-type="bibr" rid="bibr64-0897190012448309">64</xref>
<xref ref-type="bibr" rid="bibr65-0897190012448309"/>
<xref ref-type="bibr" rid="bibr66-0897190012448309"/>–<xref ref-type="bibr" rid="bibr67-0897190012448309">67</xref>
</sup> The median AUCs of the morphine metabolite increases from PM to EM to UM.<sup>
<xref ref-type="bibr" rid="bibr59-0897190012448309">59</xref>
</sup> The <italic>CYP2D6*3</italic>, <italic>*4</italic>, <italic>*5</italic>, <italic>*6</italic>, and<italic>*7</italic> alleles have been reported to account for the majority of decreased <italic>CYP2D6</italic> enzyme activity.<sup>
<xref ref-type="bibr" rid="bibr61-0897190012448309">61</xref>,<xref ref-type="bibr" rid="bibr63-0897190012448309">63</xref>
</sup> In addition, the decreased activity of <italic>CYP2D6</italic> in IMs has been shown to result from *9 and *10 alleles.<sup>
<xref ref-type="bibr" rid="bibr61-0897190012448309">61</xref>
</sup> Gene duplication of <italic>CYP2D6</italic> found in UMs is associated with higher plasma concentration and AUCs of morphine than in EMs.<sup>
<xref ref-type="bibr" rid="bibr59-0897190012448309">59</xref>
</sup>
</p>
</sec>
<sec id="section14-0897190012448309">
<title>Population Prevalence</title>
<p>Data pertaining to the population prevalence of codeine polymorphisms and metabolizer types are estimates only based on the studied populations. In the case of <italic>CYP2D6</italic>, the allele frequencies have been studied among European caucasians, Asians, and African Americans with variations found in <italic>CYP2D6*4</italic>, <italic>*5</italic>, and <italic>*10</italic>.<sup>
<xref ref-type="bibr" rid="bibr68-0897190012448309">68</xref>
</sup> The most prevalent variant allele in caucasians is <italic>CYP2D6*4</italic>, ranging from 12% to 21%.<sup>
<xref ref-type="bibr" rid="bibr68-0897190012448309">68</xref>
</sup> Other alleles found in caucasians include <italic>CYP2D6*3</italic> (1%-2%), <italic>*5 </italic>(2%-7%), and <italic>*6</italic> (1%).<sup>
<xref ref-type="bibr" rid="bibr68-0897190012448309">68</xref>
</sup> Asians have the highest frequency (38%-70%) of <italic>CYP2D6*10</italic>; other alleles found in Asians include <italic>CYP2D6*4</italic> (&lt;1%) and *<italic>5</italic> (4%-6%).<sup>
<xref ref-type="bibr" rid="bibr68-0897190012448309">68</xref>
</sup> African Americans have the lowest prevalence rates for <italic>CYP2D6*4</italic> (2%), <italic>CYP2D6</italic>*<italic>5</italic> (4%), and <italic>CYP2D6</italic>*<italic>10</italic> (6%).<sup>
<xref ref-type="bibr" rid="bibr68-0897190012448309">68</xref>
</sup>
</p>
<p>The prevalence rates of <italic>CYP2D6 </italic>PMs are observed in caucasians (5%-10%), followed by African Americans (3%) and Asians (1%).<sup>
<xref ref-type="bibr" rid="bibr62-0897190012448309">62</xref>,<xref ref-type="bibr" rid="bibr69-0897190012448309">69</xref>
</sup> The prevalence rates of <italic>CYP2D6 </italic>UMs are observed in Europeans (3% in northern Europe, 1%-10% in western Europe, and 10% in southern Europe) and Saudi Arabians (10%-30% in northeast African countries).<sup>
<xref ref-type="bibr" rid="bibr70-0897190012448309">70</xref>
<xref ref-type="bibr" rid="bibr71-0897190012448309"/>–<xref ref-type="bibr" rid="bibr72-0897190012448309">72</xref>
</sup> The prevalence rates of <italic>CYP2D6</italic> UMs have also been reported in Ethiopians (29%).<sup>
<xref ref-type="bibr" rid="bibr60-0897190012448309">60</xref>
</sup>
</p>
</sec>
<sec id="section15-0897190012448309">
<title>Clinical Relevance</title>
<p>There is no definitive study reporting the efficacy of codeine associated with <italic>CYP2D6 </italic>polymorphisms. However, a study evaluating oxycodone (which has a similar chemical structure with codeine and is metabolized by <italic>CYP2D6</italic>) showed that PMs have a 2- to 20-fold decrease in analgesic effects compared to EMs, whereas the UMs had a 1.5- to 6-fold increase in analgesic effects.<sup>
<xref ref-type="bibr" rid="bibr73-0897190012448309">73</xref>
</sup> However, there was no noticeable reduction in analgesic effects comparing PMs and EMs when oxycodone was given intravenously in a postoperative study.<sup>
<xref ref-type="bibr" rid="bibr73-0897190012448309">73</xref>
</sup> Other studies have shown that an increased pain threshold is found in EMs but not in PMs.<sup>
<xref ref-type="bibr" rid="bibr62-0897190012448309">62</xref>,<xref ref-type="bibr" rid="bibr74-0897190012448309">74</xref>
</sup> The PMs have impaired <italic>O</italic>-demethylation; therefore, the analgesic effect of codeine may not be exerted in PMs.<sup>
<xref ref-type="bibr" rid="bibr58-0897190012448309">58</xref>
</sup> Even though PMs may not experience analgesic effects expected from codeine, they can still develop side effects (eg, sedation, headaches, dizziness, and dry mouth), which may be related to codeine itself rather than its metabolites.<sup>
<xref ref-type="bibr" rid="bibr75-0897190012448309">75</xref>
</sup> UMs experience greater analgesic effects but increased risks for opiate toxicity.<sup>
<xref ref-type="bibr" rid="bibr59-0897190012448309">59</xref>,<xref ref-type="bibr" rid="bibr76-0897190012448309">76</xref>,<xref ref-type="bibr" rid="bibr77-0897190012448309">77</xref>
</sup>
</p>
<p>Evidence regarding the effect of <italic>CYP2D6 </italic>polymorphisms on codeine toxicity is primarily derived from case reports in neonates from breast-feeding UMs.<sup>
<xref ref-type="bibr" rid="bibr78-0897190012448309">78</xref>
</sup> A case report described an adverse drug event related to codeine in a breast-feeding mother taking codeine 30 mg and paracetamol 600 mg for postpartum episiotomy pain management.<sup>
<xref ref-type="bibr" rid="bibr78-0897190012448309">78</xref>,<xref ref-type="bibr" rid="bibr79-0897190012448309">79</xref>
</sup> Her codeine dosage on day 1 was 60 mg (2 tablets) every 12 hours. However, due to side effects of somnolence and constipation, she took half of the dose from day 2 to day 14. Unfortunately, her 13-day-old baby died from a morphine overdose with a serum concentration of 70 ng/mL (neonates breast-fed by mothers receiving codeine typically have morphine serum concentrations of 0-2.2 ng/mL).<sup>
<xref ref-type="bibr" rid="bibr80-0897190012448309">80</xref>
</sup> The morphine concentration found in her breast milk stored on day 10 was 87 ng/mL (normal range is 1.9-2.5 ng/mL for doses of 60 mg every 6 hours). The mother was genotyped and determined to be an UM of codeine (heterozygous for a <italic>CYP2D6*2A</italic> allele with <italic>CYP2D6</italic>*2 × 2 gene duplication).<sup>
<xref ref-type="bibr" rid="bibr78-0897190012448309">78</xref>
</sup> The correlation between increased codeine concentrations and adverse effects in breast-feeding neonates has been observed in multiple studies.<sup>
<xref ref-type="bibr" rid="bibr81-0897190012448309">81</xref>
<xref ref-type="bibr" rid="bibr82-0897190012448309"/>–<xref ref-type="bibr" rid="bibr83-0897190012448309">83</xref>
</sup> Subsequently, the FDA issued a warning, which was included in codeine’s prescribing information, stating that “maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants” and that “If a codeine containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Mothers using codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breast-feeding, breathing difficulties, and decreased tone, in their baby.”<sup>
<xref ref-type="bibr" rid="bibr56-0897190012448309">56</xref>,<xref ref-type="bibr" rid="bibr84-0897190012448309">84</xref>
</sup>
</p>
<p>UMs have a higher rate of sedation compared to EMs (91% vs 50%, <italic>P </italic>= .069).<sup>
<xref ref-type="bibr" rid="bibr59-0897190012448309">59</xref>
</sup> Other potential side effects for UMs include euphoria, dizziness, and visual disturbances<sup>
<xref ref-type="bibr" rid="bibr76-0897190012448309">76</xref>,<xref ref-type="bibr" rid="bibr77-0897190012448309">77</xref>,<xref ref-type="bibr" rid="bibr85-0897190012448309">85</xref>
</sup> or more severe symptoms such as extreme sleepiness, confusion, shallow breathing, or respiratory depression.<sup>
<xref ref-type="bibr" rid="bibr56-0897190012448309">56</xref>
</sup> Inhibitors of <italic>CYP2D6</italic> will produce a phenotype similar to that of PMs (ie, lack of analgesic effect). Therefore, potential adverse drug interactions between codeine and <italic>CYP2D6</italic> inhibitors should be monitored.<sup>
<xref ref-type="bibr" rid="bibr56-0897190012448309">56</xref>
</sup>
</p>
</sec>
<sec id="section16-0897190012448309">
<title>Testing Availability and Recommendations</title>
<p>Currently, the AmpliChip<sup>®</sup> DNA microarray, which can detect 33 <italic>CYP2D6</italic> alleles, is the only approved test for <italic>CYP2D6</italic> polymorphisms in the United States.<sup>
<xref ref-type="bibr" rid="bibr86-0897190012448309">86</xref>,<xref ref-type="bibr" rid="bibr87-0897190012448309">87</xref>
</sup> Laboratory monitoring is not necessary and no formal recommendation is required prior to initiation of codeine therapy.<sup>
<xref ref-type="bibr" rid="bibr79-0897190012448309">79</xref>,<xref ref-type="bibr" rid="bibr84-0897190012448309">84</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section17-0897190012448309">
<title>Carbamazepine</title>
<sec id="section18-0897190012448309">
<title>Background</title>
<p>Carbamazepine is an anticonvulsant that is indicated for partial and generalized seizures, trigeminal neuralgia, and bipolar disorder.<sup>
<xref ref-type="bibr" rid="bibr88-0897190012448309">88</xref>,<xref ref-type="bibr" rid="bibr89-0897190012448309">89</xref>
</sup> The exact mechanism of action is unknown, but it has been shown to block the voltage-gated sodium channels. Carbamazepine is primarily metabolized by <italic>CYP3A4 </italic>to an active metabolite, carbamazepine-10,11-epoxide.<sup>
<xref ref-type="bibr" rid="bibr88-0897190012448309">88</xref>
</sup> Carbamazepine has been linked to life-threatening idiosyncratic, type B adverse drug reactions, compared with type A reactions which are dose dependent.<sup>
<xref ref-type="bibr" rid="bibr90-0897190012448309">90</xref>
</sup> These reactions can be severe cutaneous reactions ranging from Stevens-Johnson syndrome (SJS) to toxic epidermal necrolysis (TEN). The incidence of SJS/TEN is less than 2 patients per million per year<sup>
<xref ref-type="bibr" rid="bibr91-0897190012448309">91</xref>
</sup> and the rate of death with these conditions (in absence of carbamazepine) range from 5% and 35% for SJS and TEN, respectively.<sup>
<xref ref-type="bibr" rid="bibr92-0897190012448309">92</xref>
</sup> Recently, investigators have discovered an association with human leukocyte antigen (<italic>HLA</italic>)<italic>-B*1502</italic> allele and the risk of SJS and TEN, specifically in Asians, who are prescribed carbamazepine. Most recently, <italic>HLA*3101</italic> and <italic>HLA*1511 </italic>alleles have been recognized as potentially contributing to hypersensitivity reactions.<sup>
<xref ref-type="bibr" rid="bibr93-0897190012448309">93</xref>
<xref ref-type="bibr" rid="bibr94-0897190012448309"/>–<xref ref-type="bibr" rid="bibr95-0897190012448309">95</xref>
</sup>
</p>
</sec>
<sec id="section19-0897190012448309">
<title>Gene/Allele of Interest and Functional Effect</title>
<p>Due to early observations of hypersensitivity reactions in families and identical twins, the HLA has been a primary target for analysis of SJS/TEN reactions, which also tend to be familial in pattern.<sup>
<xref ref-type="bibr" rid="bibr96-0897190012448309">96</xref>
</sup> The <italic>HLA-B*1502</italic> allele and its association with SJS/TEN appears to be phenotype specific in that the allele is not associated with other hypersensitivity reactions due to carbamazepine, such as mild maculopapular eruptions (MPEs) or drug reactions with eosinophilia systemic symptoms.<sup>
<xref ref-type="bibr" rid="bibr97-0897190012448309">97</xref>,<xref ref-type="bibr" rid="bibr98-0897190012448309">98</xref>
</sup> The relationship between <italic>HLA-B*1502</italic> and SJS/TEN appears to be drug specific in that the allele does not predict SJS/TEN by drugs other than carbamazepine.<sup>
<xref ref-type="bibr" rid="bibr99-0897190012448309">99</xref>
</sup> However, other aromatic anticonvulsants such as phenytoin, oxcarbazepine, and lamotrigine may also cause similar hypersensitivity reactions in persons with the <italic>HLA-B*1502</italic> allele.<sup>
<xref ref-type="bibr" rid="bibr100-0897190012448309">100</xref>
</sup> The SJS/TEN hypersensitivity reactions have been theorized to be due to a noncovalent interaction between carbamazepine and <italic>HLA-B*1502 </italic>complex, leading to a CD8+-mediated cell death.<sup>
<xref ref-type="bibr" rid="bibr97-0897190012448309">97</xref>,<xref ref-type="bibr" rid="bibr101-0897190012448309">101</xref>
</sup>
</p>
</sec>
<sec id="section20-0897190012448309">
<title>Population Prevalence</title>
<p>The high incidence of carbamazepine-induced SJS/TEN in Asians is correlated with the high frequency of <italic>HLA-B*1502 </italic>in the same population. The population prevalence of the allele is estimated to range from 10% to 15% in people from China (Han Chinese), Indonesia, Malaysia, Taiwan, Thailand, the Phillipines, and Vietnam, 2% to 8% in people from South Asia and less than 1% in Japanese, Koreans, African Americans, Europeans, and Hispanics.<sup>
<xref ref-type="bibr" rid="bibr102-0897190012448309">102</xref>
<xref ref-type="bibr" rid="bibr103-0897190012448309"/>–<xref ref-type="bibr" rid="bibr104-0897190012448309">104</xref>
</sup>
</p>
</sec>
<sec id="section21-0897190012448309">
<title>Clinical Relevance</title>
<p>While a preliminary study has been published regarding the role of microsomal epoxide hydrolase and its prediction of maintenance doses of carbamazepine,<sup>
<xref ref-type="bibr" rid="bibr105-0897190012448309">105</xref>
</sup> there is no definitive study that has shown any specific gene/allele to accurately predict doses or clinical efficacy of carbamazepine. The most confirmed data are related to the toxicity associated with <italic>HLA-B*1502</italic> and carbamazepine treatment. It was previously shown that caucasians who tested positive for the <italic>HLA-B*1502 </italic>allele were not at risk for carbamazepine-induced hypersensitivity.<sup>
<xref ref-type="bibr" rid="bibr106-0897190012448309">106</xref>
</sup> In the landmark study of 44 Han Chinese patients, there was 100% association with the <italic>HLA-B*1502</italic> allele and carbamazepine-induced SJS/TEN.<sup>
<xref ref-type="bibr" rid="bibr107-0897190012448309">107</xref>
</sup> A follow-up study showed 59 of 60 patients with carbamazepine-induced SJS/TEN tested positive for the <italic>HLA-B*1502</italic> allele.<sup>
<xref ref-type="bibr" rid="bibr98-0897190012448309">98</xref>
</sup> The one patient who did not test positive for the <italic>HLA-B*1502</italic> allele tested positive for the <italic>HLA-B*1558</italic> allele. In comparison, 6 out of 144 controls (tolerant to carbamazepine) were found to be carriers for the <italic>HLA-B*1502</italic> allele (OR = 1357, 95% confidence interval [CI]: 193.4-8838.3, <italic>P</italic> = 1.6 × 10<sup>−41</sup>).<sup>
<xref ref-type="bibr" rid="bibr98-0897190012448309">98</xref>
</sup> In a separate study, a significant difference in the SJS/TEN incidence was found among patients who received carbamazepine depending on whether they were <italic>HLA-B*1502</italic> carriers (100%) or noncarriers (14.5%).<sup>
<xref ref-type="bibr" rid="bibr103-0897190012448309">103</xref>
</sup>
</p>
<p>In a study of 4877 Taiwanese patients who were candidates for carbamazepine therapy, 7.7% of the patients testing positive for the <italic>HLA-B*1502</italic> allele were given an alternative medication or advised to continue their prestudy medication. The remaining 92.3% of the patients who tested negative for the <italic>HLA-B*1502</italic> allele were advised to take carbamazepine.<sup>
<xref ref-type="bibr" rid="bibr108-0897190012448309">108</xref>
</sup> Mild transient rash occurred in 4.3% of subjects. SJS/TEN did not develop in any <italic>HLA-B*1502</italic>-negative patient and when compared to historical controls was statistically significant (0% vs 0.23%, <italic>P</italic> &lt; .001).<sup>
<xref ref-type="bibr" rid="bibr108-0897190012448309">108</xref>
</sup>
</p>
<p>In addition to Chinese and Taiwanese patients, the <italic>HLA-B*1502</italic> allele was studied in Thai patients in 2 studies. A case–control study was conducted in a Thai population in which the odds ratio for developing carbamazepine-induced SJS/TEN was 54.76 (95%CI: 14.62-205.13, <italic>P</italic> = 2.89 × 10<sup>−12</sup>) among those testing positive for <italic>HLA-B*1502</italic>.<sup>
<xref ref-type="bibr" rid="bibr109-0897190012448309">109</xref>
</sup> The positive predictive value and negative predictive value of the <italic>HLA-B*1502 </italic>allele were 1.92% and 99.96%, respectively. Another study showed a strong association between <italic>HLA-B*1502</italic> and carbamazepine- and phenytoin-induced SJS but not MPE.<sup>
<xref ref-type="bibr" rid="bibr110-0897190012448309">110</xref>
</sup> Of the 81 patients with epilepsy, 31 subjects had antiepileptic drug-induced SJS/MPE. <italic>HLA-B*1502</italic> was associated with carbamazepine-induced SJS and phenytoin-induced SJS (<italic>P</italic> = .005 and <italic>P</italic> = .0005, respectively).</p>
<p>As discussed before, the <italic>HLA-B*1502</italic> allele may increase the risk of toxicity from other anticonvulsant drugs (lamotrigine, oxcarbazepine, and phenytoin) by contributing to SJS/TEN.<sup>
<xref ref-type="bibr" rid="bibr98-0897190012448309">98</xref>,<xref ref-type="bibr" rid="bibr111-0897190012448309">111</xref>,<xref ref-type="bibr" rid="bibr112-0897190012448309">112</xref>
</sup> In a case–control study, <italic>HLA-B*1502</italic> was present in 8 (30.8%) of 26 patients who received phenytoin and developed SJS/TEN (OR = 5.1, 95% CI: 1.8-15.1, <italic>P</italic> = .0041) and 3 (100%) of 3 patients who were tolerant to carbamazepine (OR = 80.7, 95% CI: 3.8-1714.4, <italic>P</italic> = 8.4 × 10<sup>−4</sup>). This was theorized to be partially due to similarities in aromatic structure between carbamazepine, oxcarbazepine, phenytoin, and lamotrigine.<sup>
<xref ref-type="bibr" rid="bibr98-0897190012448309">98</xref>
</sup> Clinically, there is an estimated 20% to 30% cross-reactivity probability between these drugs.<sup>
<xref ref-type="bibr" rid="bibr113-0897190012448309">113</xref>,<xref ref-type="bibr" rid="bibr114-0897190012448309">114</xref>
</sup>
</p>
<p>In addition to <italic>HLA-B*1502</italic>, multiple HLA alleles have been recently identified as potential markers for carbamazepine-induced hypersensitivity reactions. The <italic>HLA-A*3101</italic> has been associated with carbamazepine-induced hypersensitivity reactions in Japanese and Europeans.<sup>
<xref ref-type="bibr" rid="bibr94-0897190012448309">94</xref>,<xref ref-type="bibr" rid="bibr95-0897190012448309">95</xref>
</sup> Among Japanese, the <italic>HLA-B*1511 </italic>has been shown to be a risk factor for carbamazepine-induced SJS/TEN.<sup>
<xref ref-type="bibr" rid="bibr93-0897190012448309">93</xref>
</sup> The <italic>HLA-B*1508</italic>, <italic>*1511</italic>, and <italic>*1521</italic> as well as <italic>*1502</italic> are all members of the HLA-B75 type and have been detected in studies in India and Thailand. One study reported an association with <italic>HLA-B*1518</italic>,<italic> HLA-B*5901</italic>, and <italic>HLA-C*0704 </italic>alleles and severe cutaneous adverse drug reactions.<sup>
<xref ref-type="bibr" rid="bibr115-0897190012448309">115</xref>
</sup>
</p>
</sec>
<sec id="section22-0897190012448309">
<title>Test Availability and Recommendations</title>
<p>HLA typing will indicate whether patients are positive if either 1 or 2 alleles of <italic>HLA-B*1502 </italic>are present. In 2007, the FDA recommended that all patients of Asian descent be screened for the <italic>HLA-B*1502</italic> allele before initiating carbamazepine therapy. This recommendation is also reflected in the black box warning in the prescribing information of carbamazepine.<sup>
<xref ref-type="bibr" rid="bibr88-0897190012448309">88</xref>
</sup> Therefore, prior to initiation of this drug in high-risk patients, genotyping is recommended. </p>
<p>It is important to note that patients who have been treated with carbamazepine for an extended period do not need testing for the <italic>HLA-B*1502</italic> allele. The SJS/TEN reactions generally occur within the first 2 months of treatment and even with a positive <italic>HLA-B*1502</italic> status, patients are considered to be at low risk.<sup>
<xref ref-type="bibr" rid="bibr102-0897190012448309">102</xref>
</sup> However, patients who test negative for the <italic>HLA-B*1502</italic> allele and receive carbamazepine should still be monitored clinically for development of hypersensitivity reactions since other genetic and nongenetic factors may contribute to these adverse drug reactions.</p>
</sec>
</sec>
<sec id="section23-0897190012448309">
<title>Limitations and Challenges of Pharmacogenomic Clinical Application</title>
<p>Pharmacogenomics has the potential to impact clinically relevant outcomes in drug dosing, efficacy, and toxicity, thus resulting in recommendations for testing. However, for PPIs and codeine, pharmacogenomics has not provided conclusive evidence to require such testing. A potential reason is that determining clinical relevance for some drugs will involve both genetic and nongenetic factors. Equally important is determining the extent of contribution of such factors. For example, adherence to therapy, antimicrobial resistance, and concomitant medication use are nongenetic factors that impact <italic>H pylori </italic>cure rates,<sup>
<xref ref-type="bibr" rid="bibr116-0897190012448309">116</xref>
</sup> and all may play a significant role in treating disease.</p>
<p>Due to the low prevalence of a specific variant allele in a studied population, numerous pharmacogenomic studies were conducted with small sample sizes. In PPI studies, there was an unequal distribution of homozygous EMs, heterozygous EMs, and PMs, with a smaller number of PMs (<xref ref-type="table" rid="table2-0897190012448309">Table 2</xref>). A small sample size is a study design limitation that increases the probability of an error due to a lack of sufficient statistical power. Results from such studies may not be accurate. Ideally, a pharmacogenomic study should have sufficient statistical power, with an equal stratification of subjects across groups. However, this may not be achievable as many variant alleles carry a frequency of 1% to 2% in the population.<sup>
<xref ref-type="bibr" rid="bibr5-0897190012448309">5</xref>,<xref ref-type="bibr" rid="bibr117-0897190012448309">117</xref>
</sup> In summary, caution is warranted in interpreting the clinical relevance of pharmacogenomic studies with small sample sizes.</p>
<p>Implementation of pharmacogenomic testing into clinical practice remains a major challenge due to issues related to lack of readily available resources, feasibility, level of evidence, and ethical, legal, and social issues.<sup>
<xref ref-type="bibr" rid="bibr4-0897190012448309">4</xref>
</sup> There is also suggestion that health care providers’ knowledge on evidence-based information regarding pharmacogenomics testing is lacking.<sup>
<xref ref-type="bibr" rid="bibr118-0897190012448309">118</xref>
</sup> In one study, 80% of pharmacist respondents disagreed that pharmacogenomics was an integral part of his or her pharmacy school curriculum.<sup>
<xref ref-type="bibr" rid="bibr118-0897190012448309">118</xref>
</sup> This may be due to the sample population as the majority of respondents had more than 10 years of practice experience.</p>
<p>As pharmacists are anticipated to play an important role to prepare health systems and pharmacies in this emerging field, pharmacists need to obtain current pharmacogenomic information in order to translate the evidence into clinical practice. Several evidence-based genomics and/or pharmacogenomics online resources are available (<xref ref-type="table" rid="table3-0897190012448309">Table 3</xref>). The PharmGenEd™ program is designed to provide pharmacists, physicians, students, and other health professionals access to evidence-based pharmacogenomic information. The objective of PharmGenEd™ is to help health care professionals increase awareness about current knowledge of the validity of pharmacogenomic tests and their potential clinical implications. Educational materials are designed to be relevant for clinical practice and include case vignettes for interactive learning. Continuing education lectures are available at national/regional/local professional meetings and via the program’s Web site. Using a train-the-trainer approach, the PharmGenEd™ program disseminates pharmacogenomics educational materials to qualified speakers and trainers.</p>
<table-wrap id="table3-0897190012448309" position="float">
<label>Table 3.</label>
<caption>
<p>Available Evidence-Based Genomics and/or Pharmacogenomics Online Resources</p>
</caption>
<graphic alternate-form-of="table3-0897190012448309" xlink:href="10.1177_0897190012448309-table3.tif"/>
<table>
<tbody>
<tr>
<td>1. CDC’s National Office of Public Health Genomics (http://www.cdc.gov/genomics/)</td>
</tr>
<tr>
<td>2. FDA Genomics (http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/default.htm)</td>
</tr>
<tr>
<td>3. Genetics Home Reference by the US National Library of Medicine (http://ghr.nlm.nih.gov/glossary)</td>
</tr>
<tr>
<td>4. National Human Genome Research Institute (http://www.genome.gov/)</td>
</tr>
<tr>
<td>5. Pharmacogenomics Education Program (PharmGenEd; http://pharmacogenomics.ucsd.edu/)</td>
</tr>
<tr>
<td>6. Pharmacogenomics Knowledge Base (PharmGKB; http://pharmgkb.org/)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0897190012448309">
<p>Abbreviations: CDC, Center for Disease Control and Prevention; FDA, US Food and Drug Administration.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section24-0897190012448309">
<title>Conclusions</title>
<p>There is increasing awareness of the contribution of genetic polymorphisms on impacting clinical outcomes. Although numerous studies have reported differences in PPI PK and PD variability based on <italic>CYP2C19 </italic>genotype, conflicting evidence exists regarding <italic>H pylori </italic>eradication rates for the majority of PPIs. Consequently, no formal recommendations exist to support <italic>CYP2C19 </italic>testing to predict PPI efficacy. The tragic case report of a baby death possibly related to <italic>CYP2D6 </italic>and codeine illustrates the importance of identifying patients with altered metabolism. However, <italic>CYP2D6 </italic>testing is not required prior to starting patients on codeine. In contrast, <italic>HLA-B*1502</italic> testing is required prior to initiating carbamazepine in high-risk patients due to strong supportive evidence linking <italic>HLA-B*1502 </italic>and carbamazepine-induced SJS/TEN. Limitations and challenges of pharmacogenomic clinical application exist and need to be addressed prior to implementation of testing into clinical practice.</p>
<p>Continuing Education Credit</p>
<p>The NYSCHP is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program provides 1.6 contact hours (0.16CEUs) of continuing education. Universal Activity Number is 0134-0000-12-072-H01-P. Submission of exam for CE credit expires 8/31/2015.</p>
<p>A grade of 70% or above is required to earn the CE credit. Repeat examinations will be permitted once for a grade below 70%.</p>
<p><inline-graphic xlink:href="10.1177_0897190012448309-fig2.tif"/> There is no charge to NYSCHP members. Non Members are required to submit a processing fee of $15 and most go to www.nyschp. org to pay the fee to gain access to the online quiz. In lieu of this fee, a completed membership application with your dues may be submitted.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0897190012448309">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0897190012448309">
<label>Funding</label>
<p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Materials presented in this article were made possible from the program funded by the Center for Disease Control and Prevention (CDC No. 1U38GD000070), “Pharmacogenomics Education Program: Bridging the Gap between Science and Practice” (PharmGenEd<sup>
<sc>tm</sc>
</sup>). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0897190012448309">
<label>1</label>
<citation citation-type="web">
<article-title>American Association of Pharmaceutical Scientists. Pharmacogenomics (PGx) Focus Group</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.aapsj.org/inside/focus_groups/PGX/index.asp">https://www.aapsj.org/inside/focus_groups/PGX/index.asp</ext-link>. <comment>Accessed September 9, 2011</comment>.</citation>
</ref>
<ref id="bibr2-0897190012448309">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Relling</surname>
<given-names>MV</given-names>
</name>
</person-group>. <article-title>Pharmacogenomics: translating functional genomics into rational therapeutics</article-title>. <source>Science</source>. <year>1999</year>;<volume>286</volume>(<issue>5439</issue>):<fpage>487</fpage>–<lpage>491</lpage>.</citation>
</ref>
<ref id="bibr3-0897190012448309">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Court</surname>
<given-names>MH</given-names>
</name>
</person-group>. <article-title>A pharmacogenomics primer</article-title>. <source>J Clin Pharmacol</source>. <year>2007</year>;<volume>47</volume>(<issue>9</issue>):<fpage>1087</fpage>–<lpage>1103</lpage>.</citation>
</ref>
<ref id="bibr4-0897190012448309">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>GM</given-names>
</name>
</person-group>. <article-title>Pharmacogenomics: bridging the gap between science and practice</article-title>. <source>J Am Pharm Assoc</source>. <year>2010</year>;<volume>50</volume>(<issue>1</issue>):<fpage>e1</fpage>–<lpage>14</lpage>; <comment>quiz e15-17</comment>.</citation>
</ref>
<ref id="bibr5-0897190012448309">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davaalkham</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hayashida</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tsuchiya</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population</article-title>. <source>Drug Metab Dispos</source>. <year>2009</year>;<volume>37</volume>(<issue>10</issue>):<fpage>1991</fpage>–<lpage>1993</lpage>.</citation>
</ref>
<ref id="bibr6-0897190012448309">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dendukuri</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Khetani</surname>
<given-names>K</given-names>
</name>
<name>
<surname>McIsaac</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis</article-title>. <source>CMAJ</source>. <year>2007</year>;<volume>176</volume>(<issue>10</issue>):<fpage>1429</fpage>–<lpage>1434</lpage>.</citation>
</ref>
<ref id="bibr7-0897190012448309">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogawa</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Echizen</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Drug–drug interaction profiles of proton pump inhibitors</article-title>. <source>Clin Pharmacokinet</source>. <year>2010</year>;<volume>49</volume>(<issue>8</issue>):<fpage>509</fpage>–<lpage>533</lpage>.</citation>
</ref>
<ref id="bibr8-0897190012448309">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Klotz</surname>
<given-names>U</given-names>
</name>
</person-group>. <article-title>Proton pump inhibitors: an update of their clinical use and pharmacokinetics</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2008</year>;<volume>64</volume>(<issue>10</issue>):<fpage>935</fpage>–<lpage>951</lpage>.</citation>
</ref>
<ref id="bibr9-0897190012448309">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagymasi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mullner</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Herszenyi</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>Update on the pharmacogenomics of proton pump inhibitors</article-title>. <source>Pharmacogenomics</source>. <year>2011</year>;<volume>12</volume>(<issue>6</issue>):<fpage>873</fpage>–<lpage>888</lpage>.</citation>
</ref>
<ref id="bibr10-0897190012448309">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kita</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sakaeda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Baba</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors</article-title>. <source>Biol Pharm Bull</source>. <year>2003</year>;<volume>26</volume>(<issue>3</issue>):<fpage>386</fpage>–<lpage>390</lpage>.</citation>
</ref>
<ref id="bibr11-0897190012448309">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>VandenBranden</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ring</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Binkley</surname>
<given-names>SN</given-names>
</name>
<etal/>
</person-group> <article-title>Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor</article-title>. <source>Pharmacogenetics</source>. <year>1996</year>;<volume>6</volume>(<issue>1</issue>):<fpage>81</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr12-0897190012448309">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romkes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Faletto</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Blaisdell</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group> <article-title>Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily</article-title>. <source>Biochemistry</source>. <year>1991</year>;<volume>30</volume>(<issue>13</issue>):<fpage>3247</fpage>–<lpage>3255</lpage>.</citation>
</ref>
<ref id="bibr13-0897190012448309">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaphiropoulos</surname>
<given-names>PG</given-names>
</name>
</person-group>. <article-title>RNA molecules containing exons originating from different members of the cytochrome P450 2C gene subfamily (CYP2C) in human epidermis and liver</article-title>. <source>Nucleic Acids Res</source>. <year>1999</year>;<volume>27</volume>(<issue>13</issue>):<fpage>2585</fpage>–<lpage>2590</lpage>.</citation>
</ref>
<ref id="bibr14-0897190012448309">
<label>14</label>
<citation citation-type="web">
<collab collab-type="author">Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee</collab>. <ext-link ext-link-type="uri" xlink:href="http://www.cypalleles.ki.se/">http://www.cypalleles.ki.se/</ext-link>. <comment>Accessed September 20, 2011</comment>.</citation>
</ref>
<ref id="bibr15-0897190012448309">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Morais</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Blaisdell</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans</article-title>. <source>J Biol Chem</source>. <year>1994</year>;<volume>269</volume>(<issue>22</issue>):<fpage>15419</fpage>–<lpage>15422</lpage>.</citation>
</ref>
<ref id="bibr16-0897190012448309">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blaisdell</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mohrenweiser</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Identification and functional characterization of new potentially defective alleles of human CYP2C19</article-title>. <source>Pharmacogenetics</source>. <year>2002</year>;<volume>12</volume>(<issue>9</issue>):<fpage>703</fpage>–<lpage>711</lpage>.</citation>
</ref>
<ref id="bibr17-0897190012448309">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baldwin</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Ohlsson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>RS</given-names>
</name>
<etal/>
</person-group> <article-title>Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers</article-title>. <source>Br J Clin Pharmacol</source>. <year>2008</year>;<volume>65</volume>(<issue>5</issue>):<fpage>767</fpage>–<lpage>774</lpage>.</citation>
</ref>
<ref id="bibr18-0897190012448309">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desta</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>JG</given-names>
</name>
<etal/>
</person-group> <article-title>Clinical significance of the cytochrome P450 2C19 genetic polymorphism</article-title>. <source>Clin Pharmacokinet</source>. <year>2002</year>;<volume>41</volume>(<issue>12</issue>):<fpage>913</fpage>–<lpage>958</lpage>.</citation>
</ref>
<ref id="bibr19-0897190012448309">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizutani</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>PM frequencies of major CYPs in Asians and Caucasians</article-title>. <source>Drug Metab Rev</source>. <year>2003</year>;<volume>35</volume>(<issue>2-3</issue>):<fpage>99</fpage>–<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr20-0897190012448309">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roh</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Tybring</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>CYP2C19 genotype and phenotype determined by omeprazole in a Korean population</article-title>. <source>Pharmacogenetics</source>. <year>1996</year>;<volume>6</volume>(<issue>6</issue>):<fpage>547</fpage>–<lpage>551</lpage>.</citation>
</ref>
<ref id="bibr21-0897190012448309">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sim</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Risinger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>ML</given-names>
</name>
<etal/>
</person-group> <article-title>A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants</article-title>. <source>Clin Pharmacol Ther</source>. <year>2006</year>;<volume>79</volume>(<issue>1</issue>):<fpage>103</fpage>–<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr22-0897190012448309">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bertino</surname>
<given-names>JS</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Gaedigk</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker</article-title>. <source>Clin Pharmacol Ther</source>. <year>2002</year>;<volume>72</volume>(<issue>2</issue>):<fpage>192</fpage>–<lpage>199</lpage>.</citation>
</ref>
<ref id="bibr23-0897190012448309">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furuta</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ohashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kamata</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of genetic differences in omeprazole metabolism on cure rates for <italic>Helicobacter pylori</italic> infection and peptic ulcer</article-title>. <source>Ann Intern Med</source>. <year>1998</year>;<volume>129</volume>(<issue>12</issue>):<fpage>1027</fpage>–<lpage>1030</lpage>.</citation>
</ref>
<ref id="bibr24-0897190012448309">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furuta</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ohashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans</article-title>. <source>Clin Pharmacol Ther</source>. <year>1999</year>;<volume>66</volume>(<issue>3</issue>):<fpage>265</fpage>–<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr25-0897190012448309">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Aoyama</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kita</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects</article-title>. <source>Pharm Res</source>. <year>2001</year>;<volume>18</volume>(<issue>6</issue>):<fpage>721</fpage>–<lpage>727</lpage>.</citation>
</ref>
<ref id="bibr26-0897190012448309">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shirai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Furuta</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Moriyama</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group> <article-title>Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2001</year>;<volume>15</volume>(<issue>12</issue>):<fpage>1929</fpage>–<lpage>1937</lpage>.</citation>
</ref>
<ref id="bibr27-0897190012448309">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furuta</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ohashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kosuge</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans</article-title>. <source>Clin Pharmacol Ther</source>. <year>1999</year>;<volume>65</volume>(<issue>5</issue>):<fpage>552</fpage>–<lpage>561</lpage>.</citation>
</ref>
<ref id="bibr28-0897190012448309">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goddard</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Jessa</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Barrett</surname>
<given-names>DA</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice</article-title>. <source>Gastroenterology</source>. <year>1996</year>;<volume>111</volume>(<issue>2</issue>):<fpage>358</fpage>–<lpage>367</lpage>.</citation>
</ref>
<ref id="bibr29-0897190012448309">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goddard</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Spiller</surname>
<given-names>RC</given-names>
</name>
</person-group>. <article-title>The effect of omeprazole on gastric juice viscosity, pH and bacterial counts</article-title>. <source>Aliment Pharmacol Ther</source>. <year>1996</year>;<volume>10</volume>(<issue>1</issue>):<fpage>105</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr30-0897190012448309">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grayson</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Eliopoulos</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Ferraro</surname>
<given-names>MJ</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of varying pH on the susceptibility of <italic>Campylobacter pylori</italic> to antimicrobial agents</article-title>. <source>Eur J Clin Microbiol Infect Dis</source>. <year>1989</year>;<volume>8</volume>(<issue>10</issue>):<fpage>888</fpage>–<lpage>889</lpage>.</citation>
</ref>
<ref id="bibr31-0897190012448309">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Midolo</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Turnidge</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>JR</given-names>
</name>
<etal/>
</person-group> <article-title>Oxygen concentration influences proton pump inhibitor activity against <italic>Helicobacter pylori</italic> in vitro</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1996</year>;<volume>40</volume>(<issue>6</issue>):<fpage>1531</fpage>–<lpage>1533</lpage>.</citation>
</ref>
<ref id="bibr32-0897190012448309">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aoyama</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tanigawara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kita</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for <italic>Helicobacter pylori</italic> eradication in cytochrome P450 2C19 poor metabolizers</article-title>. <source>J Gastroenterol</source>. <year>1999</year>;<volume>34</volume>(<issue>suppl 11</issue>):<fpage>80</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr33-0897190012448309">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sapone</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vaira</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Trespidi</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>The clinical role of cytochrome p450 genotypes in <italic>Helicobacter pylori</italic> management</article-title>. <source>Am J Gastroenterol</source>. <year>2003</year>;<volume>98</volume>(<issue>5</issue>):<fpage>1010</fpage>–<lpage>1015</lpage>.</citation>
</ref>
<ref id="bibr34-0897190012448309">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheu</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Kao</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>HC</given-names>
</name>
<etal/>
</person-group> <article-title>Esomeprazole 40 mg twice daily in triple therapy and the efficacy of <italic>Helicobacter pylori</italic> eradication related to CYP2C19 metabolism</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2005</year>;<volume>21</volume>(<issue>3</issue>):<fpage>283</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr35-0897190012448309">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Take</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ishiki</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for <italic>Helicobacter pylori</italic> infection</article-title>. <source>Am J Gastroenterol</source>. <year>2003</year>;<volume>98</volume>(<issue>11</issue>):<fpage>2403</fpage>–<lpage>2408</lpage>.</citation>
</ref>
<ref id="bibr36-0897190012448309">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanigawara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Aoyama</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kita</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by <italic>Helicobacter pylori</italic>
</article-title>. <source>Clin Pharmacol Ther</source>. <year>1999</year>;<volume>66</volume>(<issue>5</issue>):<fpage>528</fpage>–<lpage>534</lpage>.</citation>
</ref>
<ref id="bibr37-0897190012448309">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Padol</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Thabane</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>The effect of CYP2C19 polymorphisms on <italic>H. pylori</italic> eradication rate in dual and triple first-line PPI therapies: a meta-analysis</article-title>. <source>Am J Gastroenterol</source>. <year>2006</year>;<volume>101</volume>(<issue>7</issue>):<fpage>1467</fpage>–<lpage>1475</lpage>.</citation>
</ref>
<ref id="bibr38-0897190012448309">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for <italic>Helicobacter pylori</italic> eradication: a meta-analysis</article-title>. <source>Helicobacter</source>. <year>2008</year>;<volume>13</volume>(<issue>6</issue>):<fpage>532</fpage>–<lpage>541</lpage>.</citation>
</ref>
<ref id="bibr39-0897190012448309">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dojo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Azuma</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Effects of CYP2C19 gene polymorphism on cure rates for <italic>Helicobacter pylori</italic> infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan</article-title>. <source>Dig Liver Dis</source>. <year>2001</year>;<volume>33</volume>(<issue>8</issue>):<fpage>671</fpage>–<lpage>675</lpage>.</citation>
</ref>
<ref id="bibr40-0897190012448309">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyoshi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ishiki</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for <italic>Helicobacter pylori</italic> infection in relation to CYP2C19 genetic polymorphism</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2001</year>;<volume>16</volume>(<issue>7</issue>):<fpage>723</fpage>–<lpage>728</lpage>.</citation>
</ref>
<ref id="bibr41-0897190012448309">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inaba</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>Randomized open trial for comparison of proton pump inhibitors in triple therapy for <italic>Helicobacter pylori</italic> infection in relation to CYP2C19 genotype</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2002</year>;<volume>17</volume>(<issue>7</issue>):<fpage>748</fpage>–<lpage>753</lpage>.</citation>
</ref>
<ref id="bibr42-0897190012448309">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furuta</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shirai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Takashima</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of genotypic differences in CYP2C19 on cure rates for <italic>Helicobacter pylori</italic> infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin</article-title>. <source>Clin Pharmacol Ther</source>. <year>2001</year>;<volume>69</volume>(<issue>3</issue>):<fpage>158</fpage>–<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr43-0897190012448309">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isomoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Furusu</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group> <article-title>Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of <italic>Helicobacter pylori</italic>
</article-title>. <source>Helicobacter</source>. <year>2003</year>;<volume>8</volume>(<issue>2</issue>):<fpage>111</fpage>–<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr44-0897190012448309">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawabata</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Habu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tomioka</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of <italic>Helicobacter pylori</italic> infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2003</year>;<volume>17</volume>(<issue>2</issue>):<fpage>259</fpage>–<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr45-0897190012448309">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okudaira</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Furuta</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shirai</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>Concomitant dosing of famotidine with a triple therapy increases the cure rates of <italic>Helicobacter pylori</italic> infections in patients with the homozygous extensive metabolizer genotype of CYP2C19</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2005</year>;<volume>21</volume>(<issue>4</issue>):<fpage>491</fpage>–<lpage>497</lpage>.</citation>
</ref>
<ref id="bibr46-0897190012448309">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwab</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schaeffeler</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Klotz</surname>
<given-names>U</given-names>
</name>
<etal/>
</person-group> <article-title>CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of <italic>Helicobacter pylori</italic>
</article-title>. <source>Clin Pharmacol Ther</source>. <year>2004</year>;<volume>76</volume>(<issue>3</issue>):<fpage>201</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr47-0897190012448309">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furuta</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shirai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Takashima</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Effects of genotypic differences in CYP2C19 status on cure rates for <italic>Helicobacter pylori</italic> infection by dual therapy with rabeprazole plus amoxicillin</article-title>. <source>Pharmacogenetics</source>. <year>2001</year>;<volume>11</volume>(<issue>4</issue>):<fpage>341</fpage>–<lpage>348</lpage>.</citation>
</ref>
<ref id="bibr48-0897190012448309">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hokari</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sugiyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy of triple therapy with rabeprazole for <italic>Helicobacter pylori</italic> infection and CYP2C19 genetic polymorphism</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2001</year>;<volume>15</volume>(<issue>9</issue>):<fpage>1479</fpage>–<lpage>1484</lpage>.</citation>
</ref>
<ref id="bibr49-0897190012448309">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>JK</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy of triple therapy with rabeprazole for <italic>Helicobacter pylori</italic> infection in relation to CYP2C19 genotype</article-title>. <source>Korean J Gastroenterol</source>. <year>2003</year>;<volume>42</volume>(<issue>6</issue>):<fpage>468</fpage>–<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr50-0897190012448309">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miki</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Aoyama</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sakai</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of <italic>Helicobacter pylori</italic> infection with lansoprazole- or rabeprazole-based triple therapy in Japan</article-title>. <source>Eur J Gastroenterol Hepatol</source>. <year>2003</year>;<volume>15</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr51-0897190012448309">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurzawski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gawronska-Szklarz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wrzesniewska</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of CYP2C19*17 gene variant on <italic>Helicobacter pylori</italic> eradication in peptic ulcer patients</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2006</year>;<volume>62</volume>(<issue>10</issue>):<fpage>877</fpage>–<lpage>880</lpage>.</citation>
</ref>
<ref id="bibr52-0897190012448309">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gawronska-Szklarz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Siuda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kurzawski</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of <italic>Helicobacter pylori</italic> infection by triple therapy with pantoprazole, amoxicillin, and metronidazole</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2010</year>;<volume>66</volume>(<issue>7</issue>):<fpage>681</fpage>–<lpage>687</lpage>.</citation>
</ref>
<ref id="bibr53-0897190012448309">
<label>53</label>
<citation citation-type="web">
<collab collab-type="author">FDA</collab>. <article-title>Table of Pharmacogenomic Biomarkers in Drug Labels</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm">http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm</ext-link>. <comment>Accessed September 20, 2011</comment>.</citation>
</ref>
<ref id="bibr54-0897190012448309">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Htun</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention</article-title>. <source>Vasc Health Risk Manag</source>. <year>2011</year>;<volume>7</volume>:<fpage>399</fpage>–<lpage>404</lpage>.</citation>
</ref>
<ref id="bibr55-0897190012448309">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abraham</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Hlatky</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Antman</surname>
<given-names>EM</given-names>
</name>
<etal/>
</person-group> <article-title>ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>122</volume>(<issue>24</issue>):<fpage>2619</fpage>–<lpage>2633</lpage>.</citation>
</ref>
<ref id="bibr56-0897190012448309">
<label>56</label>
<citation citation-type="web">
<collab collab-type="author">Codeine sulfate tablets</collab>. <article-title>Prescribing Information</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf</ext-link>. <comment>Accessed August 30, 2011</comment>.</citation>
</ref>
<ref id="bibr57-0897190012448309">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caraco</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tateishi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Guengerich</surname>
<given-names>FP</given-names>
</name>
<etal/>
</person-group> <article-title>Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity</article-title>. <source>Drug Metab Dispos</source>. <year>1996</year>;<volume>24</volume>(<issue>7</issue>):<fpage>761</fpage>–<lpage>764</lpage>.</citation>
</ref>
<ref id="bibr58-0897190012448309">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dayer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Desmeules</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Leemann</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)</article-title>. <source>Biochem Biophys Res Commun</source>. <year>1988</year>;<volume>152</volume>(<issue>1</issue>):<fpage>411</fpage>–<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr59-0897190012448309">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirchheiner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tzvetkov</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication</article-title>. <source>Pharmacogenomics J</source>. <year>2007</year>;<volume>7</volume>(<issue>4</issue>):<fpage>257</fpage>–<lpage>265</lpage>.</citation>
</ref>
<ref id="bibr60-0897190012448309">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cascorbi</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication</article-title>. <source>Eur J Clin Invest</source>. <year>2003</year>;<volume>33</volume>(<issue>suppl 2</issue>):<fpage>17</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr61-0897190012448309">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ingelman-Sundberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sim</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects</article-title>. <source>Pharmacol Ther</source>. <year>2007</year>;<volume>116</volume>(<issue>3</issue>):<fpage>496</fpage>–<lpage>526</lpage>.</citation>
</ref>
<ref id="bibr62-0897190012448309">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lurcott</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone</article-title>. <source>Anesth Prog</source>. <year>1998</year>;<volume>45</volume>(<issue>4</issue>):<fpage>154</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr63-0897190012448309">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Beaman</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>LS</given-names>
</name>
<etal/>
</person-group> <article-title>Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial</article-title>. <source>Pharmacogenetics</source>. <year>2000</year>;<volume>10</volume>(<issue>7</issue>):<fpage>583</fpage>–<lpage>590</lpage>.</citation>
</ref>
<ref id="bibr64-0897190012448309">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borges</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Desta</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group> <article-title>Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients</article-title>. <source>J Clin Pharmacol</source>. <year>2010</year>;<volume>50</volume>(<issue>4</issue>):<fpage>450</fpage>–<lpage>458</lpage>.</citation>
</ref>
<ref id="bibr65-0897190012448309">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaedigk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gotschall</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Forbes</surname>
<given-names>NS</given-names>
</name>
<etal/>
</person-group> <article-title>Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data</article-title>. <source>Pharmacogenetics</source>. <year>1999</year>;<volume>9</volume>(<issue>6</issue>):<fpage>669</fpage>–<lpage>682</lpage>.</citation>
</ref>
<ref id="bibr66-0897190012448309">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaedigk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Pearce</surname>
<given-names>RE</given-names>
</name>
<etal/>
</person-group> <article-title>The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype</article-title>. <source>Clin Pharmacol Ther</source>. <year>2008</year>;<volume>83</volume>(<issue>2</issue>):<fpage>234</fpage>–<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr67-0897190012448309">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zanger</surname>
<given-names>UM</given-names>
</name>
<name>
<surname>Raimundo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Eichelbaum</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry</article-title>. <source>Naunyn Schmiedebergs Arch Pharmacol</source>. <year>2004</year>;<volume>369</volume>(<issue>1</issue>):<fpage>23</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr68-0897190012448309">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bradford</surname>
<given-names>LD</given-names>
</name>
</person-group>. <article-title>CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants</article-title>. <source>Pharmacogenomics</source>. <year>2002</year>;<volume>3</volume>(<issue>2</issue>):<fpage>229</fpage>–<lpage>243</lpage>.</citation>
</ref>
<ref id="bibr69-0897190012448309">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caraco</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sheller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>Pharmacogenetic determination of the effects of codeine and prediction of drug interactions</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1996</year>;<volume>278</volume>(<issue>3</issue>):<fpage>1165</fpage>–<lpage>1174</lpage>.</citation>
</ref>
<ref id="bibr70-0897190012448309">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aynacioglu</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Sachse</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bozkurt</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population</article-title>. <source>Clin Pharmacol Ther</source>. <year>1999</year>;<volume>66</volume>(<issue>2</issue>):<fpage>185</fpage>–<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr71-0897190012448309">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madadi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Moretti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Djokanovic</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>Guidelines for maternal codeine use during breastfeeding</article-title>. <source>Can Fam Physician</source>. <year>2009</year>;<volume>55</volume>(<issue>11</issue>):<fpage>1077</fpage>–<lpage>1078</lpage>.</citation>
</ref>
<ref id="bibr72-0897190012448309">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McLellan</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Oscarson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Seidegard</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians</article-title>. <source>Pharmacogenetics</source>. <year>1997</year>;<volume>7</volume>(<issue>3</issue>):<fpage>187</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr73-0897190012448309">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samer</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Daali</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone</article-title>. <source>Br J Pharmacol</source>. <year>2010</year>;<volume>160</volume>(<issue>4</issue>):<fpage>907</fpage>–<lpage>918</lpage>.</citation>
</ref>
<ref id="bibr74-0897190012448309">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sindrup</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Brosen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bjerring</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine</article-title>. <source>Clin Pharmacol Ther</source>. <year>1990</year>;<volume>48</volume>(<issue>6</issue>):<fpage>686</fpage>–<lpage>693</lpage>.</citation>
</ref>
<ref id="bibr75-0897190012448309">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eckhardt</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ammon</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation</article-title>. <source>Pain</source>. <year>1998</year>;<volume>76</volume>(<issue>1-2</issue>):<fpage>27</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr76-0897190012448309">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciszkowski</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Madadi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>MS</given-names>
</name>
<etal/>
</person-group> <article-title>Codeine, ultrarapid-metabolism genotype, and postoperative death</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>361</volume>(<issue>8</issue>):<fpage>827</fpage>–<lpage>828</lpage>.</citation>
</ref>
<ref id="bibr77-0897190012448309">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Frengell</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>ML</given-names>
</name>
<etal/>
</person-group> <article-title>Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine</article-title>. <source>Ther Drug Monit</source>. <year>1997</year>;<volume>19</volume>(<issue>5</issue>):<fpage>543</fpage>–<lpage>544</lpage>.</citation>
</ref>
<ref id="bibr78-0897190012448309">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koren</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cairns</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chitayat</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother</article-title>. <source>Lancet</source>. <year>2006</year>;<volume>368</volume>(<issue>9536</issue>):<fpage>704</fpage>.</citation>
</ref>
<ref id="bibr79-0897190012448309">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurtz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Black Golde</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Berlinger</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Ethical considerations in CYP2D6 genotype testing for codeine-prescribed breastfeeding mothers</article-title>. <source>Clin Pharmacol Ther</source>. <year>2010</year>;<volume>88</volume>(<issue>6</issue>):<fpage>760</fpage>–<lpage>762</lpage>.</citation>
</ref>
<ref id="bibr80-0897190012448309">
<label>80</label>
<citation citation-type="web">
<collab collab-type="author">Codeine</collab>. <article-title>Breast feeding</article-title>; <year>2011</year>. <ext-link ext-link-type="uri" xlink:href="http://www.clinicalpharmacology-ip.com/Forms/Monograph/monograph.aspx?cpnum=146&amp;sec=monpreg">http://www.clinicalpharmacology-ip.com/Forms/Monograph/monograph.aspx?cpnum=146&amp;sec=monpreg</ext-link>. <comment>Accessed August 30, 2011</comment>.</citation>
</ref>
<ref id="bibr81-0897190012448309">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferner</surname>
<given-names>RE</given-names>
</name>
</person-group>. <article-title>Did the drug cause death? Codeine and breastfeeding</article-title>. <source>Lancet</source>. <year>2008</year>;<volume>372</volume>(<issue>9639</issue>):<fpage>606</fpage>–<lpage>608</lpage>.</citation>
</ref>
<ref id="bibr82-0897190012448309">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gasche</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Daali</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fathi</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Codeine intoxication associated with ultrarapid CYP2D6 metabolism</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>351</volume>(<issue>27</issue>):<fpage>2827</fpage>–<lpage>2831</lpage>.</citation>
</ref>
<ref id="bibr83-0897190012448309">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madadi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Koren</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use</article-title>. <source>Pharmacogenomics</source>. <year>2008</year>;<volume>9</volume>(<issue>9</issue>):<fpage>1267</fpage>–<lpage>1284</lpage>.</citation>
</ref>
<ref id="bibr84-0897190012448309">
<label>84</label>
<citation citation-type="web">
<collab collab-type="author">FDA</collab>. <article-title>FDA Public Health Advisory. Use of Codeine by Some Breastfeeding Mothers May Lead to Life-Threatening Side Effects in Nursing Babies</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/Drugs/DrugSafetyPostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm054717.htm">http://www.fda.gov/Drugs/DrugSafetyPostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm054717.htm</ext-link>.</citation>
</ref>
<ref id="bibr85-0897190012448309">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lotsch</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Skarke</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liefhold</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives</article-title>. <source>Clin Pharmacokinet</source>. <year>2004</year>;<volume>43</volume>(<issue>14</issue>):<fpage>983</fpage>–<lpage>1013</lpage>.</citation>
</ref>
<ref id="bibr86-0897190012448309">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Leon</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>AmpliChip CYP450 test: personalized medicine has arrived in psychiatry</article-title>. <source>Expert Rev Mol Diagn</source>. <year>2006</year>;<volume>6</volume>(<issue>3</issue>):<fpage>277</fpage>–<lpage>286</lpage>.</citation>
</ref>
<ref id="bibr87-0897190012448309">
<label>87</label>
<citation citation-type="web">
<collab collab-type="author">Roche</collab>. <article-title>AmpliChip CYP450 Test</article-title>. <ext-link ext-link-type="uri" xlink:href="http://molecular.roche.com/ASSAYS/Pages/AmpliChipCYP450Test.aspx">http://molecular.roche.com/ASSAYS/Pages/AmpliChipCYP450Test.aspx</ext-link>. <comment>Accessed August 30, 2011</comment>.</citation>
</ref>
<ref id="bibr88-0897190012448309">
<label>88</label>
<citation citation-type="book">
<collab collab-type="author">Tegretol (Carbamazepine) &amp; Tegretol XR (Carbamazepine Extended-Release Tablets)</collab>. <article-title>Prescribing Information</article-title>. <publisher-loc>East Hanover, NJ</publisher-loc>: <publisher-name>Novartis Pharmaceuticals Corporation</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr89-0897190012448309">
<label>89</label>
<citation citation-type="book">
<collab collab-type="author">Equetro (Carbamazepine Extended-Release)</collab>. <article-title>Prescribing Information</article-title>. <publisher-loc>Parsippany, NJ</publisher-loc>: <publisher-name>Validus Pharmaceuticals LLC</publisher-name>; <year>2010</year>.</citation>
</ref>
<ref id="bibr90-0897190012448309">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomes</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Demoly</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Epidemiology of hypersensitivity drug reactions</article-title>. <source>Curr Opin Allergy Clin Immunol</source>. <year>2005</year>;<volume>5</volume>(<issue>4</issue>):<fpage>309</fpage>–<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr91-0897190012448309">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rzany</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hering</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Mockenhaupt</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis</article-title>. <source>Br J Dermatol</source>. <year>1996</year>;<volume>135</volume>(<issue>1</issue>):<fpage>6</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr92-0897190012448309">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roujeau</surname>
<given-names>JC</given-names>
</name>
</person-group>. <article-title>The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification</article-title>. <source>J Invest Dermatol</source>. <year>1994</year>;<volume>102</volume>(<issue>6</issue>):<fpage>28S</fpage>–<lpage>30S</lpage>.</citation>
</ref>
<ref id="bibr93-0897190012448309">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaniwa</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Aihara</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients</article-title>. <source>Epilepsia</source>. <year>2010</year>;<volume>51</volume>(<issue>12</issue>):<fpage>2461</fpage>–<lpage>2465</lpage>.</citation>
</ref>
<ref id="bibr94-0897190012448309">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCormack</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Alfirevic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bourgeois</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>364</volume>(<issue>12</issue>):<fpage>1134</fpage>–<lpage>1143</lpage>.</citation>
</ref>
<ref id="bibr95-0897190012448309">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozeki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mushiroda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yowang</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population</article-title>. <source>Hum Mol Genet</source>. <year>2011</year>;<volume>20</volume>(<issue>5</issue>):<fpage>1034</fpage>–<lpage>1041</lpage>.</citation>
</ref>
<ref id="bibr96-0897190012448309">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edwards</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Hubbard</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Aylett</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins</article-title>. <source>Postgrad Med J</source>. <year>1999</year>;<volume>75</volume>(<issue>889</issue>):<fpage>680</fpage>–<lpage>681</lpage>.</citation>
</ref>
<ref id="bibr97-0897190012448309">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mauri-Hellweg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bettens</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mauri</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine</article-title>. <source>J Immunol</source>. <year>1995</year>;<volume>155</volume>(<issue>1</issue>):<fpage>462</fpage>–<lpage>472</lpage>.</citation>
</ref>
<ref id="bibr98-0897190012448309">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hung</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Jee</surname>
<given-names>SH</given-names>
</name>
<etal/>
</person-group> <article-title>Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions</article-title>. <source>Pharmacogenet Genomics</source>. <year>2006</year>;<volume>16</volume>(<issue>4</issue>):<fpage>297</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr99-0897190012448309">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hung</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>LB</given-names>
</name>
<etal/>
</person-group> <article-title>HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2005</year>;<volume>102</volume>(<issue>11</issue>):<fpage>4134</fpage>–<lpage>4139</lpage>.</citation>
</ref>
<ref id="bibr100-0897190012448309">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aihara</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Pharmacogenetics of cutaneous adverse drug reactions</article-title>. <source>J Dermatol</source>. <year>2011</year>;<volume>38</volume>(<issue>3</issue>):<fpage>246</fpage>–<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr101-0897190012448309">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naisbitt</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Britschgi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones</article-title>. <source>Mol Pharmacol</source>. <year>2003</year>;<volume>63</volume>(<issue>3</issue>):<fpage>732</fpage>–<lpage>741</lpage>.</citation>
</ref>
<ref id="bibr102-0897190012448309">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>CY</given-names>
</name>
<etal/>
</person-group> <article-title>Pharmacogenetics of toxic epidermal necrolysis</article-title>. <source>Expert Opin Pharmacother</source>. <year>2010</year>;<volume>11</volume>(<issue>13</issue>):<fpage>2153</fpage>–<lpage>2162</lpage>.</citation>
</ref>
<ref id="bibr103-0897190012448309">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lonjou</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Borot</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>A marker for Stevens-Johnson syndrome: ethnicity matters</article-title>. <source>Pharmacogenomics J</source>. <year>2006</year>;<volume>6</volume>(<issue>4</issue>):<fpage>265</fpage>–<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr104-0897190012448309">
<label>104</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Middleton</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Allele frequencies in Worldwide populations</article-title>. <ext-link ext-link-type="uri" xlink:href="www.allelefrequencies.net">www.allelefrequencies.net</ext-link>. <comment>Accessed September 21, 2011</comment>.</citation>
</ref>
<ref id="bibr105-0897190012448309">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makmor-Bakry</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sills</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Hitiris</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing</article-title>. <source>Clin Neuropharmacol</source>. <year>2009</year>;<volume>32</volume>(<issue>4</issue>):<fpage>205</fpage>–<lpage>212</lpage>.</citation>
</ref>
<ref id="bibr106-0897190012448309">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alfirevic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jorgensen</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Williamson</surname>
<given-names>PR</given-names>
</name>
<etal/>
</person-group> <article-title>HLA-B locus in Caucasian patients with carbamazepine hypersensitivity</article-title>. <source>Pharmacogenomics</source>. <year>2006</year>;<volume>7</volume>(<issue>6</issue>):<fpage>813</fpage>–<lpage>818</lpage>.</citation>
</ref>
<ref id="bibr107-0897190012448309">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>HS</given-names>
</name>
<etal/>
</person-group> <article-title>Medical genetics: a marker for Stevens-Johnson syndrome</article-title>. <source>Nature</source>. <year>2004</year>;<volume>428</volume>(<issue>6982</issue>):<fpage>486</fpage>.</citation>
</ref>
<ref id="bibr108-0897190012448309">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>CS</given-names>
</name>
<etal/>
</person-group> <article-title>Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>364</volume>(<issue>12</issue>):<fpage>1126</fpage>–<lpage>1133</lpage>.</citation>
</ref>
<ref id="bibr109-0897190012448309">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tassaneeyakul</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Tiamkao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jantararoungtong</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population</article-title>. <source>Epilepsia</source>. <year>2010</year>;<volume>51</volume>(<issue>5</issue>):<fpage>926</fpage>–<lpage>930</lpage>.</citation>
</ref>
<ref id="bibr110-0897190012448309">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Locharernkul</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Loplumlert</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Limotai</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population</article-title>. <source>Epilepsia</source>. <year>2008</year>;<volume>49</volume>(<issue>12</issue>):<fpage>2087</fpage>–<lpage>2091</lpage>.</citation>
</ref>
<ref id="bibr111-0897190012448309">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuehn</surname>
<given-names>BM</given-names>
</name>
</person-group>. <article-title>FDA: epilepsy drugs may carry skin risks for Asians</article-title>. <source>JAMA</source>. <year>2008</year>;<volume>300</volume>(<issue>24</issue>):<fpage>2845</fpage>.</citation>
</ref>
<ref id="bibr112-0897190012448309">
<label>112</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Juo</surname>
<given-names>CG</given-names>
</name>
<etal/>
</person-group> <article-title>HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome</article-title>. <source>J Allergy Clin Immunol</source>. <year>2007</year>;<volume>120</volume>(<issue>4</issue>):<fpage>870</fpage>–<lpage>877</lpage>.</citation>
</ref>
<ref id="bibr113-0897190012448309">
<label>113</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirsch</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Arif</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nahm</surname>
<given-names>EA</given-names>
</name>
<etal/>
</person-group> <article-title>Cross-sensitivity of skin rashes with antiepileptic drug use</article-title>. <source>Neurology</source>. <year>2008</year>;<volume>71</volume>(<issue>19</issue>):<fpage>1527</fpage>–<lpage>1534</lpage>.</citation>
</ref>
<ref id="bibr114-0897190012448309">
<label>114</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alvestad</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lydersen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brodtkorb</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Cross-reactivity pattern of rash from current aromatic antiepileptic drugs</article-title>. <source>Epilepsy Res</source>. <year>2008</year>;<volume>80</volume>(<issue>2-3</issue>):<fpage>194</fpage>–<lpage>200</lpage>.</citation>
</ref>
<ref id="bibr115-0897190012448309">
<label>115</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ikeda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yamazaki</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions</article-title>. <source>Epilepsia</source>. <year>2010</year>;<volume>51</volume>(<issue>2</issue>):<fpage>297</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr116-0897190012448309">
<label>116</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klotz</surname>
<given-names>U</given-names>
</name>
</person-group>. <article-title>Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs)</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2009</year>;<volume>65</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>2</lpage>.</citation>
</ref>
<ref id="bibr117-0897190012448309">
<label>117</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eiselt</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Domanski</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Zibat</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Identification and functional characterization of eight CYP3A4 protein variants</article-title>. <source>Pharmacogenetics</source>. <year>2001</year>;<volume>11</volume>(<issue>5</issue>):<fpage>447</fpage>–<lpage>458</lpage>.</citation>
</ref>
<ref id="bibr118-0897190012448309">
<label>118</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCullough</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Formea</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>KD</given-names>
</name>
<etal/>
</person-group> <article-title>Assessment of the pharmacogenomics educational needs of pharmacists</article-title>. <source>Am J Pharm Educ</source>. <year>2011</year>;<volume>75</volume>(<issue>3</issue>):<fpage>51</fpage>.</citation>
</ref>
</ref-list>
</back>
</article>